High-throughput functional mapping of KCNE1 variants provides moderate-strength evidence for ACMG/AMP functional criteria, aiding in the reclassification of variants of uncertain significance in arrhythmias.
Answers are grounded in this paper and cite their sources.
Supports moderate-strength KCNE1 functional evidence for ACMG/AMP; leaves open clinical VUS reclassification pending human validation.
Background: ) subunit. KCNE1 variants are associated with long QT syndrome and atrial fibrillation. However, most variants have insufficient evidence of clinical consequences and thus limited clinical utility. Results: Here, we demonstrate the power of variant effect mapping, which couples saturation mutagenesis with high-throughput sequencing, to ascertain the function of thousands of protein coding KCNE1 variants. We comprehensively assayed KCNE1 variant cell surface expression (2,554/2,709 possible single amino acid variants) and function (2,539 variants). We identified 470 loss-of-surface expression and 588 loss-of-function variants. Out of the 588 loss-of-function variants, only 155 had low cell surface expression. The latter half of the protein is dispensable for protein trafficking but essential for channel function. 22 of the 30 KCNE1 residues (73%) highly intolerant of variation were in predicted close contact with binding partners KCNQ1 or calmodulin. Our data were highly concordant with gold standard electrophysiological data (ρ = -0.65), population and patient cohorts (32/38 concordant variants), and computational metrics (ρ = -0.55). Our data provide moderate-strength evidence for the ACMG/AMP functional criteria for benign and pathogenic variants. Conclusions: channel biology and help reclassify variants of uncertain significance.
No takes yet. Share an insight, caveat, or question.
Muhammad et al. (2023) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: